Clinical trials
Chronic Leukemia clinical trials
Below are recruiting chronic leukemia clinical trials, each written for real people, not researchers. We’re tracking 306 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05794880Recruiting
Immunotherapy lowering immune cells before transplant in children
This trial tests a special immune-cell “preparation” treatment (called T-cell and B-cell depletion) with adjusted anti-thymocyte globulin (ATG) dosing before a stem cell transplant. It aims to reduce immune-related transplant complications in people under 25 with certain blood cancers in a specific remission status.
Milwaukee, WisconsinAges birth–25 years - NCT05805605RecruitingPhase 2
Low-intensity stem cell transplant with donor cells and blood-protection
This Phase 2 study tests a low-intensity bone marrow/stem cell transplant using a matched donor plus two medicines to help prevent the donor cells from attacking you. It aims to treat certain blood cancers—especially when standard treatment has not fully worked or when you are in remission but at higher risk.
Minneapolis, MinnesotaAges Up to 75 years - NCT06059391RecruitingPhase 2
Vaccine for stem cell donors to prevent CMV
This trial tests whether giving a CMV vaccine to stem cell donors can help protect recipients from CMV infection after transplant. It is for adults with specific blood cancers who are CMV-positive and have a matched related donor.
Duarte, CaliforniaAges 18–75 - NCT06082804Recruiting
Nurse-led management for chronic myeloid leukemia
This trial tests whether having a specially trained nurse manage your care can improve outcomes for people with chronic myeloid leukemia (CML) who take oral medication. It may be a good fit if you are starting or changing oral therapy.
AvignonAges 18 years+ - NCT06119269Recruiting
Ponatinib for chronic phase CML
This study looks at how the drug ponatinib works in people with chronic phase CML. It aims to understand how the body handles the drug and if it helps control the leukemia.
CagliariAges 18 years+ - NCT06163430RecruitingPhase 1/Phase 2
Testing a new pill for CML after other treatments
This study tests a new targeted pill called TERN-701 for people with chronic myeloid leukemia (CML) that has not responded well to or caused side effects from other targeted therapies. The goal is to see if it is safe and effective.
Birmingham, AlabamaAges 18 years+ - NCT06191887RecruitingPhase 1
BAFFR-targeting CAR-T cells for relapsed B-cell blood cancers
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BAFFR on B-cell blood cancers. The goal is to see if it can shrink tumors when given after a short chemotherapy course to prepare the body.
Jacksonville, FloridaAges 18 years+ - NCT06229860Recruiting
Personality and CML medication adherence study
This study looks at how a person's personality might affect how well they take their CML medication. It's for people with chronic phase CML who are taking certain targeted therapy pills (imatinib, dasatinib, bosutinib, or nilotinib).
Orange, CaliforniaAges 18 years+ - NCT06236724RecruitingPhase 2
Asciminib for newly diagnosed chronic myeloid leukemia
This study tests a targeted pill called asciminib for people newly diagnosed with chronic-phase CML. It aims to see if this drug is safe and effective as an early treatment option.
Houston, TexasAges 18 years+ - NCT06355583RecruitingPhase 2
Gut bacteria transplant before stem cell transplant
This trial tests whether giving a transplant of healthy gut bacteria (fecal microbiota transplant) before a stem cell transplant can improve outcomes for people with certain blood cancers or bone marrow disorders.
Birmingham, EnglandAges 18 years+ - NCT06364423RecruitingPhase 1/Phase 2
CAR T-cell therapy for CD19-positive leukemias and lymphomas
This trial tests a new immune therapy that uses your own cells (CAR T-cells) to find and attack cancer cells with the CD19 protein. It is for people with certain types of leukemia or lymphoma that have not responded to other treatments.
Bethesda, MarylandAges 18–120 - NCT06368414RecruitingPhase 2
Stopping TKI in CML after asciminib
This trial tests if people with chronic myeloid leukemia (CML) who have already tried to stop their TKI medication once and lost a deep remission, can safely stop their TKI again after taking a newer drug called asciminib. The goal is to stay in remission (no detectable leukemia) without needing daily medication.
Incheon, IncheonAges 19 years+ - NCT06409936RecruitingPhase 2
Early use of asciminib for new CML patients
This trial tests the drug asciminib for people newly diagnosed with chronic myeloid leukemia (CML) who have been on treatment for less than a month. It aims to see if early treatment with asciminib is safe and effective.
BarcelonaAges 18 years+ - NCT06523556RecruitingPhase 1/Phase 2
Axatilimab with or without azacitidine for advanced blood cancers
This trial tests a new drug, axatilimab, given alone or with another drug (azacitidine) for people with advanced forms of blood cancers like certain leukemias and myelofibrosis. It may help if your disease has not responded to earlier treatments or if you are starting treatment for the first time.
Columbus, OhioAges 18 years+ - NCT03934372RecruitingPhase 1/Phase 2
Ponatinib for children with relapsed or hard-to-treat cancers
This trial tests a targeted therapy called ponatinib in children whose leukemia, lymphoma, or solid tumor has come back or hasn't improved with standard treatments. The drug works by blocking signals that help cancer cells grow, and the study looks at how safe and effective it is for different cancer types.
GhentAges 1–17 - NCT07020533RecruitingPhase 1
CMV vaccine for stem cell transplant recipients
This trial tests a vaccine designed to boost immunity against CMV (a common virus) and prevent active CMV infection in people receiving a half-matched stem cell transplant. It may help protect you from CMV-related complications after transplant.
Duarte, CaliforniaAges 18–75 - NCT06644183RecruitingPhase 1/Phase 2
Triple therapy for relapsed CLL after prior treatments
This trial tests three drugs—roginolisib, venetoclax, and rituximab—for people with CLL that has come back or not responded after at least two prior treatments, including a BTK inhibitor. The goal is to see if this combination is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT06680661RecruitingPhase 2
Double cord blood transplant with abatacept for GVHD prevention
This trial tests whether adding abatacept to a double cord blood transplant can prevent graft-versus-host disease (GVHD) in people with certain blood cancers. You may qualify if you have high-risk leukemia or other blood disorders and do not have a matched related or unrelated donor.
Cleveland, OhioAges 18–65 - NCT06712810RecruitingPhase 1
Q702 for blood cancers and histiocytic disorders
This study tests an experimental pill called Q702 for people with certain blood cancers and related disorders (like histiocytoses, myelofibrosis, and lymphomas) that have not responded to standard treatments. It aims to see if Q702 is safe and effective.
Scottsdale, ArizonaAges 18 years+ - NCT06802315RecruitingPhase 2
Radiation therapy before stem cell transplant for high-risk blood cancers
This trial tests a precise type of radiation called intensity modulated total marrow irradiation before a stem cell transplant. It aims to destroy cancer cells while reducing side effects for patients with high-risk leukemia or myelodysplastic syndrome.
Chicago, IllinoisAges 18–65 - NCT06817720RecruitingPhase 2
Olverembatinib for newly diagnosed chronic phase CML
This trial tests the drug olverembatinib alone for people with newly diagnosed chronic phase CML who have not had much prior treatment. It aims to see how well the drug works and what side effects it may cause.
Houston, TexasAges 18 years+ - NCT06839053RecruitingPhase 2
Study of sonrotoclax, rituximab, and zanubrutinib for CLL, SLL, and MCL
This trial tests a combination of three drugs (sonrotoclax, rituximab, and zanubrutinib) for people with chronic lymphocytic leukemia, small lymphocytic lymphoma, or mantle cell lymphoma. The goal is to see if the combination works better than current treatments.
Seattle, WashingtonAges 18 years+ - NCT06859424RecruitingPhase 2
Testing a new GVHD prevention method after donor stem cell transplant
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
Birmingham, AlabamaAges 18–66 - NCT06928662RecruitingPhase 1/Phase 2
Chemo, radiation, and donor stem cell transplant for high-risk blood cancers
This trial tests a strong chemotherapy and radiation combo followed by a donor stem cell transplant for people with aggressive blood cancers (like AML or MDS) that haven't responded to earlier treatments or came back. It aims to help prevent the cancer from returning.
Seattle, WashingtonAges 18 years+
Hear when a new Chronic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic leukemia?
- Yes. Clin2 currently lists 306 recruiting chronic leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.